{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:56:56Z","timestamp":1781459816446,"version":"3.54.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study compared treatment persistence of individuals newly initiating treatment with rimegepant or lasmiditan for the acute treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort analysis was conducted on individuals from MarketScan (commercial and managed Medicare) newly initiating treatment with rimegepant or lasmiditan between March 2020 and December 2022. Treatment persistence was defined as the proportion of individuals with \u22651 medication refill within 12 months of the index prescription. Subgroups included individuals with chronic migraine, index lasmiditan dose (50 and 100\u2005mg) and individuals with a history of two or more uses of controlled substances (prior repeated use of controlled substances [PRUCS] defined here as opioids, butalbital, nausea medications with central nervous system action). Treatment persistence was compared between inverse probability of treatment weighting (IPTW)-adjusted cohorts using odds ratios (ORs) and 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary analysis included 16,603 rimegepant and 716 lasmiditan users. A significantly higher proportion of individuals in the rimegepant cohort were treatment persistent compared with the lasmiditan cohort (OR 3.79 [95% CI 3.23\u20134.41]). This finding remained consistent across lasmiditan dosages (50\u2005mg: 5.05 [3.87\u20136.60]; 100\u2005mg: 3.33 [2.78\u20134.00]), chronic migraine diagnosis (3.89 [3.21\u20134.71]), or PRUCS (ORs ranged from 2.78 to 4.63; all statistically significant).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rimegepant users demonstrated higher treatment persistence over 12 months compared to lasmiditan users, which could reflect better real-world treatment satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261447187","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:16:13Z","timestamp":1781169373000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9879-6638","authenticated-orcid":false,"given":"Stewart J","family":"Tepper","sequence":"first","affiliation":[{"name":"The New England Institute for Neurology and Headache, Stamford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-9388","authenticated-orcid":false,"given":"Aaron","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dagenais","sequence":"additional","affiliation":[{"name":"Pfizer Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1599-4696","authenticated-orcid":false,"given":"Carl","family":"Henriksen","sequence":"additional","affiliation":[{"name":"Henriksen Analytic Insights, LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-8621","authenticated-orcid":false,"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[{"name":"Pfizer R&D UK Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9963-6863","authenticated-orcid":false,"given":"Feng","family":"Dai","sequence":"additional","affiliation":[{"name":"Pfizer Inc"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-7099","authenticated-orcid":false,"given":"Karin","family":"Hygge Blakeman","sequence":"additional","affiliation":[{"name":"Pfizer AB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Praxis Gendolla, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e31812006365"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0846-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.4.368"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410383058"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03027.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18094872"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01343.x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241252666"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02451-x"},{"key":"e_1_3_4_15_2","unstructured":"Biohaven Pharmaceuticals I. NURTEC ODT Prescribing Information. 2020."},{"key":"e_1_3_4_16_2","unstructured":"Lilly USA L. REYVOW Prescribing Information. 2022."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01904-1"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2026.2615680"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.04.005"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103110"},{"key":"e_1_3_4_21_2","unstructured":"Kenny BJ Preuss CV. Pharmacy Prescription RequirementsStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing [Updated 2024 Jan 9]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538424\/."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1433423"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251352849"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2410930"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13642"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2732"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13544"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6663591"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12198"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261447187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261447187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261447187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T17:08:51Z","timestamp":1781456931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261447187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03331024261447187"],"URL":"https:\/\/doi.org\/10.1177\/03331024261447187","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"03331024261447187"}}